Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. [electronic resource]
Producer: 20031118Description: 56-9 p. digitalISSN:- 1526-9655
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antigens, CD -- immunology
- Antigens, CD20 -- immunology
- Antigens, Differentiation, B-Lymphocyte -- immunology
- B-Lymphocytes -- immunology
- Cell Adhesion Molecules
- Disease Progression
- Humans
- Lectins -- immunology
- Lymphoma, Non-Hodgkin -- immunology
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- immunology
- Radioimmunotherapy -- methods
- Radiopharmaceuticals
- Sialic Acid Binding Ig-like Lectin 2
- Treatment Outcome
- Yttrium Radioisotopes -- therapeutic use
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.